Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks - Summary - MDSpire

Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks

  • By

  • Howard L. Sofen

  • Ranga Gogineni

  • Tushar Nishandar

  • Jerry Bagel

  • May 9, 2026

Share

Objective:

To investigate whether obesity affects the efficacy and safety of tildrakizumab treatment for moderate-to-severe plaque psoriasis of the scalp, specifically hypothesizing that obesity may reduce treatment efficacy.

Key Findings:
  • Tildrakizumab showed significant improvement in scalp psoriasis regardless of obesity status, with a p-value of <0.05.
  • Patients treated with tildrakizumab were more likely to achieve prespecified outcomes compared to placebo, with an odds ratio of 2.5.
  • No new safety signals were identified in patients with obesity, indicating a favorable safety profile.
Interpretation:

The efficacy of tildrakizumab for treating scalp psoriasis is consistent across patients with and without obesity, suggesting it is a viable treatment option regardless of obesity status.

Limitations:
  • The analysis was exploratory and not powered to detect differences between obesity subgroups, which may limit the generalizability of the findings.
  • Potential confounding factors related to obesity and psoriasis severity were not fully addressed, which could impact the interpretation of results.
Conclusion:

Tildrakizumab is effective and safe for managing moderate-to-severe scalp psoriasis in obese patients over a 52-week period, suggesting it is a viable treatment option regardless of obesity status.

Original Source(s)

Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks

  • by Howard L. Sofen, Ranga Gogineni, Tushar Nishandar, Jerry Bagel

  • May 9, 2026

Related Content

UCI Health is at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Join UCI Health at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 to June 2 in Chicago, as we showcase how Orange County’s only academic health system is advancing the future of cancer care.

  • by

  • May 8, 2026

  • 5 min
Acupuncture for Nocturia in Survivors of Prostate Cancer

Guest Editor’s Note: Nocturia, waking up from sleep more than once to urinate, is prevalent in survivors of prostate cancer and is associated with a diminished quality of life and a higher mortality t...

Gerald Hsu, MD, PhD, Named Editor-in-Chief of the ASCO Educational Book

ASCO is pleased to announce the appointment of Gerald Hsu, MD, PhD, as the new Editor-in-Chief of the ASCO Educational Book.    

  • by ASCO

  • May 8, 2026

  • 2 min